Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Heart bypass drug showdown: which pill keeps arteries open longest?

NCT ID NCT04310995

Disease control Sponsor: Ruijin Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This study compares three common heart medications (nicorandil, diltiazem, and isosorbide mononitrate) to see which best prevents the narrowing or failure of radial artery grafts used in coronary artery bypass surgery. About 150 adults who recently had bypass surgery will take one of the three drugs for 24 weeks, with follow-up imaging and check-ups at 1 week, 24 weeks, and again after 5 years. The goal is to find the most effective anti-spasm treatment to keep grafts open and reduce future heart problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

150 people

The number who actually took part.

Started

Jun 2020

Finished

May 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age≥18 years old， * Male or female patients， * Have signed informed consent， * Have successfully received a RA-CABG surgery 1-3 days ago. Exclusion Criteria: * Previously experienced an allergy to active ingredients and/or excipients of experimental drugs, * Hypotension (defined as systolic blood pressure \< 90mmHg or diastolic blood pressure \< 60mmHg) after surgery, * Acute myocardial infarction, pulmonary congestion or cardiogenic shock after surgery, * Concomitant medications with phosphodiesterase-5 inhibitors such as sildenafil, vardenafil, tadalafil, etc, * Pathological sinus node syndrome, degree II or III atrioventricular block without cardiac pacemaker, * With contraindications for coronary computed tomography angiography (CCTA) or coronary arteriography (CAG) examination, such as iodine allergy, etc. note: patients with renal insufficiency or even end-stage receiving hemodialysis but can be tolerated by CCTA or CAG examination (judged by investigators) are eligible for inclusion, * History or evidence of ongoing alcohol or drug abuse, * Life expectancy \< 1 year judged by investigators, * Other inappropriate situations judged by investigators .

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Antispastic therapy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Antispastic therapy Coronary artery bypass graft Pilot study Radial artery grafts

Contacts and locations

Locations

  • Ruijin Hospital Shanghai Jiaotong University School of Medicine

    Shanghai, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.